Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07462182

Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction

Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction With Oligohydramnios.

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
108 (estimated)
Sponsor
Muhammad Aamir Latif · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options. Therefore, the current study was planned with the objective to evaluate the impact of enoxaparin therapy compared with standard management on neonatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR) with oligohydramnios.

Detailed description

The use of enoxaparin is not yet a standard practice in pregnancies with IUGR and oligohydramnios without overt maternal thrombophilia. Given the notable incidence of IUGR and oligohydramnios and the limited therapeutic options currently available, exploring the potential benefits of enoxaparin therapy against standard management is both clinically and socially relevant. By investigating whether enoxaparin can improve fetal outcomes in this high-risk group, the findings of this study would generate evidence that could inform future management protocols, reduce preventable perinatal morbidity and mortality, and ultimately improve neonatal survival and health in Pakistan.

Conditions

Interventions

TypeNameDescription
DRUGEnoxaparinPatients will receive standard management plus enoxaparin 40 mg subcutaneously once daily until delivery
OTHERStandard ManagementPatients will continue with standard management alone.

Timeline

Start date
2026-04-01
Primary completion
2026-09-30
Completion
2026-09-30
First posted
2026-03-10
Last updated
2026-03-10

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT07462182. Inclusion in this directory is not an endorsement.